Leber’s hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation

PURPOSE: In September 2015, the first and so far only medication for treatment of Leber’s hereditary optic neuropathy (LHON) was approved in the EU. The drug in question is idebenone (©Raxone) and has been given to all newly diagnosed patients of the University Eye Hospital Tuebingen since the appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonagel, Felix, Wilhelm, Helmut, Richter, Paul, Kelbsch, Carina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Neuro-Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016777/
https://www.ncbi.nlm.nih.gov/pubmed/33337510
http://dx.doi.org/10.1007/s00417-020-05045-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016777/
https://www.ncbi.nlm.nih.gov/pubmed/33337510
http://dx.doi.org/10.1007/s00417-020-05045-4

Ejemplares similares